CD8A and neoplasm: The lack of response to Anti-PD-L1 antibody (Atezolizumab) in a patient with metastatic urothelial cancer was found to be related to TGF-β signaling in fibroblasts that might be linked to CD8+ T cell exclusion from the tumor parenchyma.